DALLAS / Oct 01, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced that it has completed the sale of its 70% majority ownership interest in Brookwood Baptist Health in Birmingham to Orlando Health consistent with previously disclosed terms.
The completed transaction includes five hospitals – Brookwood Baptist Medical Center, Citizens Baptist Medical Center, Princeton Baptist Medical Center, Shelby Baptist Medical Center, Walker Baptist Medical Center – and other related operations.
Tenet’s Conifer Health Solutions subsidiary has entered into a ten-year contract to provide comprehensive revenue cycle management services for these operations.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$158.09 |
Daily Change: | -3.19 -1.98 |
Daily Volume: | 1,023,602 |
Market Cap: | US$14.680B |
July 22, 2025 April 29, 2025 February 12, 2025 October 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load